Pleiotropic functional properties of androgen receptor mutants in prostate cancer

Human Mutation

Volumn 30, Issue 2, 2009, Pages 145-157

  Bergerat, Jean Pierre ^a,b   Céraline, Jocelyn ^a,b  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

Androgen independency; Androgen receptor; Hormone therapy; Mutations; Prostate cancer

Indexed keywords

AMINO ACID; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; BICALUTAMIDE; CORTICOSTEROID; CYPROTERONE ACETATE; DEOXYCORTICOSTERONE; ESTRADIOL; ESTROGEN; FLUTAMIDE; GLUCOCORTICOID; HYDROXYFLUTAMIDE; LEUPRORELIN; NILUTAMIDE; PRASTERONE; PROGESTERONE; TESTOSTERONE;

CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; DNA BINDING; DRUG WITHDRAWAL; GENE MUTATION; HINGE REGION; HORMONAL THERAPY; HUMAN; LIGAND BINDING; PLEIOTROPY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN DOMAIN; REVIEW;

HUMANS; MALE; MUTANT PROTEINS; MUTATION; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 59749095425     PISSN: 10597794     EISSN: None     Source Type: Journal    
DOI: 10.1002/humu.20848     Document Type: Review

References (140)

1. Arnold JT, Isaacs JT. 2002. Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. Endocr Relat Cancer 9:61-73.
2. Avila DM, Zoppi S, McPhaul MJ. 2001. The androgen receptor (AR) in syndromes of androgen insensitivity and in prostate cancer. J Steroid Biochem Mol Biol 76:135-142.
3. Bakin RE, Gioeli D, Sikes RA, Bissonette EA, Weber MJ. 2003. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res 63:1981-1989.
4. Baron S, Manin M, Beaudoin C, Leotoing L, Communal Y, Veyssiere G, Morel L. 2004. Androgen receptor mediates non-genomic activation of phosphatidylinositol 3-OH kinase in androgen-sensitive epithelial cells. J Biol Chem 279:14579-14586.
5. Berger R, Lin DI, Nieto M, Sicinska E, Garraway LA, Adams H, Signoretti S, Hahn WC, Loda M. 2006. Androgen-dependent regulation of Her-2/neu in prostate cancer cells. Cancer Res 66:5723-5728.
6. Berrevoets CA, Umar A, Trapman J, Brinkmann AO. 2004. Differential modulation of androgen receptor transcriptional activity by the nuclear receptor co-repressor (N-CoR). Biochem J 379(Pt 3):731-738.
7. Betney R, McEwan IJ. 2003. Role of conserved hydrophobic amino acids in androgen receptor AF-1 function. J Mol Endocrinol 31:427-439.
8. Bhattacharyya RS, Krishnan AV, Swami S, Feldman D. 2006. Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells. Mol Cancer Ther 5:1539-1549.
9. Black BE, Paschal BM. 2004. Intranuclear organization and function of the androgen receptor. Trends Endocrinol Metab 15:411-417.
10. Black BE, Vitto MJ, Gioeli D, Spencer A, Afshar N, Conaway MR, Weber MJ, Paschal BM. 2004. Transient, ligand-dependent arrest of the androgen receptor in subnuclear foci alters phosphorylation and coactivator interactions. Mol Endocrinol 18:834-850.
11. Bohl CE, Wu Z, Miller DD, Bell CE, Dalton JT. 2007. Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design. J Biol Chem 282:13648-13655.
12. Brown RS, Edwards J, Dogan A, Payne H, Harland SJ, Bartlett JM, Masters JR. 2002. Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer. J Pathol 198:237-244.
13. Bruggenwirth HT, Boehmer AL, Ramnarain S, Verleun-Mooijman MC, Satijn DP, Trapman J, Grootegoed JA, Brinkmann AO. 1997. Molecular analysis of the androgen-receptor gene in a family with receptor-positive partial androgen insensitivity: an unusual type of intronic mutation. Am J Hum Genet 61:1067-1077.
14. Buchanan G, Greenberg NM, Scher HI, Harris JM, Marshall VR, Tilley WD. 2001a. Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res 7:1273-1281.
15. Buchanan G, Yang M, Harris JM, Nahm HS, Han G, Moore N, Bentel JM, Matusik RJ, Horsfall DJ, Marshall VR, Greenberg NM, Tilley WD. 2001b. Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. Mol Endocrinol 15:46-56.
16. Buchanan G, Yang M, Cheong A, Harris JM, Irvine RA, Lambert PF, Moore NL, Raynor M, Neufing PJ, Coetzee GA, Tilley WD. 2004. Structural and functional consequences of glutamine tract variation in the androgen receptor. Hum Mol Genet 13:1677-1692.
17. Butler LM, Centenera MM, Neufing PJ, Buchanan G, Choong CS, Ricciardelli C, Saint K, Lee M, Ochnik A, Yang M, Brown MP, Tilley WD. 2006. Suppression of androgen receptor signaling in prostate cancer cells by an inhibitory receptor variant. Mol Endocrinol 20:1009-1024.
18. Callewaert L, Van Tilborgh N, Claessens F. 2006. Interplay between two hormone-independent activation domains in the androgen receptor. Cancer Res 66:543-553.
19. Castagnaro M, Yandell DW, Dockhorn-Dworniczak B, Wolfe HJ, Poremba C. 1993. [Androgen receptor gene mutations and p53 gene analysis in advanced prostate cancer]. Verh Dtsch Ges Pathol 77:119-123.
20. Céraline J, Erdmann E, Erbs P, Deslandres-Cruchant M, Jacqmin D, Duclos B, Klein-Soyer C, Dufour P, Bergerat JP. 2003. A yeast-based functional assay for the detection of the mutant androgen receptor in prostate cancer. Eur J Endocrinol 148:99-110.
21. Ceraline J, Cruchant MD, Erdmann E, Erbs P, Kurtz JE, Duclos B, Jacqmin D, Chopin D, Bergerat JP. 2004. Constitutive activation of the androgen receptor by a point mutation in the hinge region: a new mechanism for androgen-independent growth in prostate cancer. Int J Cancer 108:152-157.
22. Chang CY, Walther PJ, McDonnell DP. 2001. Glucocorticoids manifest androgenic activity in a cell line derived from a metastatic prostate cancer. Cancer Res 61:8712-8717.
23. Chen G, Shukeir N, Potti A, Sircar K, Aprikian A, Goltzman D, Rabbani SA. 2004. Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer 101:1345-1356.
24. Chen G, Wang X, Zhang S, Lu Y, Sun Y, Zhang J, Li Z, Lu J. 2005. Androgen receptor mutants detected in recurrent prostate cancer exhibit diverse functional characteristics. Prostate 63:395-406.
25. Chen S, Xu Y, Yuan X, Bubley GJ, Balk SP. 2006. Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1. Proc Natl Acad Sci USA 103:15969-15974.
26. Chmelar R, Buchanan G, Need EF, Tilley W, Greenberg NM. 2007. Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int J Cancer 120:719-733.
27. Cinar B, Mukhopadhyay NK, Meng G, Freeman MR. 2007. Phosphoinositide 3-kinase-independent non-genomic signals transit from the androgen receptor to Akt1 in membrane raft microdomains. J Biol Chem 282:29584-29593.
28. Cleutjens KB, van der Korput HA, van Eekelen CC, van Rooij HC, Faber PW, Trapman J. 1997. Androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol Endocrinol 11:148-161.
29. Culig Z, Hobisch A, Cronauer MV, Cato AC, Hittmair A, Radmayr C, Eberle J, Bartsch G, Klocker H. 1993. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 7:1541-1550.
30. Culig Z, Klocker H, Bartsch G, Hobisch A. 2002. Androgen receptors in prostate cancer. Endocr Relat Cancer 9:155-170.
31. Culig Z. 2004. Androgen receptor cross-talk with cell signalling pathways. Growth Factors 22:179-184.
32. Culig Z, Comuzzi B, Steiner H, Bartsch G, Hobisch A. 2004. Expression and function of androgen receptor coactivators in prostate cancer. J Steroid Biochem Mol Biol 92:265-271.
33. Culig Z, Steiner H, Bartsch G, Hobisch A. 2005. Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem 95:497-505.
34. Dotzlaw H, Moehren U, Mink S, Cato AC, Iniguez Lluhi JA, Baniahmad A. 2002. The amino terminus of the human AR is target for corepressor action and antihormone agonism. Mol Endocrinol 16:661-673.
35. Dotzlaw H, Papaioannou M, Moehren U, Claessens F, Baniahmad A. 2003. Agonist-antagonist induced coactivator and corepressor interplay on the human androgen receptor. Mol Cell Endocrinol 213:79-85.
36. Duff J, McEwan IJ. 2005. Mutation of histidine 874 in the androgen receptor ligand-binding domain leads to promiscuous ligand activation and altered p160 coactivator interactions. Mol Endocrinol 19:2943-2954.
37. Eder IE, Hoffmann J, Rogatsch H, Schafer G, Zopf D, Bartsch G, Klocker H. 2002. Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor. Cancer Gene Ther 9:117-125.
38. Eder IE, Haag P, Bartsch G, Klocker H. 2005. Targeting the androgen receptor in hormone-refractory prostate cancer-new concepts. Future Oncol 1:93-101.
39. Edwards J, Krishna NS, Grigor KM, Bartlett JM. 2003. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 89:552-556.
40. Edwards J, Bartlett JM. 2005. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: Androgen-receptor cofactors and bypass pathways. BJU Int 95:1327-1335.
41. Elo JP, Kvist L, Leinonen K, Isomaa V, Henttu P, Lukkarinen O, Vihko P. 1995. Mutated human androgen receptor gene detected in a prostatic cancer patient is also activated by estradiol. J Clin Endocrinol Metab 80:3494-3500.
42. Feldman BJ, Feldman D. 2001. The development of androgen-independent prostate cancer. Nat Rev Cancer 1:34-45.
43. Fenton MA, Shuster TD, Fertig AM, Taplin ME, Kolvenbag G, Bubley GJ, Balk SP. 1997. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res 3:1383-1388.
44. Ford OH, 3rd, Gregory CW, Kim D, Smitherman AB, Mohler JL. 2003. Androgen receptor gene amplification and protein expression in recurrent prostate cancer. J Urol 170:1817-1821.
45. Freeman MR, Cinar B, Lu ML. 2005. Membrane rafts as potential sites of nongenomic hormonal signaling in prostate cancer. Trends Endocrinol Metab 16:273-279.
46. Gleave M, Nelson C, Chi K. 2003. Antisense targets to enhance hormone and cytotoxic therapies in advanced prostate cancer. Curr Drug Targets 4:209-221.
47. Gottlieb B, Beitel LK, Wu JH, Trifiro M. 2004. The androgen receptor gene mutations database (ARDB): 2004 update. Hum Mutat 23:527-533.
48. Gregory CW, Johnson RT, Jr, Mohler JL, French FS, Wilson EM. 2001. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 61:2892-2898.
49. Gregory CW, Fei X, Ponguta LA, He B, Bill HM, French FS, Wilson EM. 2004. Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J Biol Chem 279:7119-7130.
50. Gronemeyer H, Gustafsson JA, Laudet V. 2004. Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov 3:950-964.
51. Haag P, Bektic J, Bartsch G, Klocker H, Eder IE. 2005. Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. J Steroid Biochem Mol Biol 96:251-258.
52. Haapala K, Hyytinen ER, Roiha M, Laurila M, Rantala I, Helin HJ, Koivisto PA. 2001. Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide. Lab Invest 81:1647-1651.
53. Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, Miyamoto M. 2003. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 63:149-153.
54. Hara T, Kouno J, Nakamura K, Kusaka M, Yamaoka M. 2005. Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells. Prostate 65:268-275.
55. Heinlein CA, Chang C. 2002. The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. Mol Endocrinol 16:2181-2187.
56. Heinlein CA, Chang C. 2004. Androgen receptor in prostate cancer. Endocr Rev 25:276-308.
57. Hobisch A, Ramoner R, Fuchs D, Godoy-Tundidor S, Bartsch G, Klocker H, Culig Z. 2001. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. Clin Cancer Res 7:2941-2948.
58. Hyytinen ER, Haapala K, Thompson J, Lappalainen I, Roiha M, Rantala I, Helin HJ, Janne OA, Vihinen M, Palvimo JJ, Koivisto PA. 2002. Pattern of somatic androgen receptor gene mutations in patients with hormone-refractory prostate cancer. Lab Invest 82:1591-1598.
59. Jaaskelainen J, Mongan NP, Harland S, Hughes IA. 2006. Five novel androgen receptor gene mutations associated with complete androgen insensitivity syndrome. Hum Mutat 27:291.
60. Jagla M, Feve M, Kessler P, Lapouge G, Erdmann E, Serra S, Bergerat JP, Ceraline J. 2007. A splicing variant of the androgen receptor detected in a metastatic prostate cancer exhibits exclusively cytoplasmic actions. Endocrinology 148:4334-4343.
61. James AJ, Agoulnik IU, Harris JM, Buchanan G, Tilley WD, Marcelli M, Lamb DJ, Weigel NL. 2002. A novel androgen receptor mutant, A748 T, exhibits hormone concentration-dependent defects in nuclear accumulation and activity despite normal hormone-binding affinity. Mol Endocrinol 16:2692-2705.
62. Jenster G, van der Korput HA, van Vroonhoven C, van der Kwast TH, Trapman J, Brinkmann AO. 1991. Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol 5:1396-1404.
63. Jenster G, van der Korput HA, Trapman J, Brinkmann AO. 1995. Identification of two transcription activation units in the N-terminal domain of the human androgen receptor. J Biol Chem 270:7341-7346.
64. Karan D, Lin MF, Johansson SL, Batra SK. 2003. Current status of the molecular genetics of human prostatic adenocarcinomas. Int J Cancer 103:285-293.
65. Katagiri T, Takahashi N. 2002. Regulatory mechanisms of osteoblast and osteoclast differentiation. Oral Dis 8:147-159.
66. Ko YJ, Devi GR, London CA, Kayas A, Reddy MT, Iversen PL, Bubley GJ, Balk SP. 2004. Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers. J Urol 172:1140-1144.
67. Kousteni S, Bellido T, Plotkin LI, O'Brien CA, Bodenner DL, Han L, Han K, DiGregorio GB, Katzenellenbogen JA, Katzenellenbogen BS, Roberson PK, Weinstein RS, Jilka RL, Manolagas SC. 2001. Nongenotropic, sex-non-specific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 104:719-730.
68. Kousteni S, Han L, Chen JR, Almeida M, Plotkin LI, Bellido T, Manolagas SC. 2003. Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids. J Clin Invest 111:1651-1664.
69. Krishnan AV, Zhao XY, Swami S, Brive L, Peehl DM, Ely KR, Feldman D. 2002. A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen-independent prostate cancer. Endocrinology 143:1889-1900.
70. Lamb DJ, Puxeddu E, Malik N, Stenoien DL, Nigam R, Saleh GY, Mancini M, Weigel NL, Marcelli M. 2003. Molecular analysis of the androgen receptor in ten prostate cancer specimens obtained before and after androgen ablation. J Androl 24:215-225.
71. Lapouge G, Marcias G, Erdmann E, Kessler P, Cruchant M, Serra S, Bergerat JP, Céraline J. 2008. Specific properties of a C-terminal truncated androgen receptor detected in hormone refractory prostate cancer. Adv Exp Med Biol 617:529-534.
72. Lapouge G, Erdmann E, Marcias G, Jagla M, Monge A, Kessler P, Serra S, Lang H, Jacqmin D, Bergerat JP, Céraline J. 2007. Unexpected paracrine action of prostate cancer cells harboring a new class of androgen receptor mutation-a new paradigm for cooperation among prostate tumor cells. Int J Cancer 121:1238-1244.
73. Lee SO, Lou W, Hou M, de Miguel F, Gerber L, Gao AC. 2003. Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin Cancer Res 9:370-376.
74. Lee SO, Chun JY, Nadiminty N, Lou W, Gao AC. 2007. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression. Prostate 67:764-773.
75. Li L, Ren CH, Tahir SA, Ren C, Thompson TC. 2003. Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol Cell Biol 23:9389-9404.
76. Li W, Cavasotto CN, Cardozo T, Ha S, Dang T, Taneja SS, Logan SK, Garabedian MJ. 2005. Androgen receptor mutations identified in prostate cancer and androgen insensitivity syndrome display aberrant ART-27 coactivator function. Mol Endocrinol 19:2273-2282.
77. Liao X, Tang S, Thrasher JB, Griebling TL, Li B. 2005. Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer. Mol Cancer Ther 4:505-515.
78. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T. 2001. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61:3550-3555.
79. Logothetis CJ, Lin SH. 2005. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 5:21-28.
80. Magi-Galluzzi C, Xu X, Hlatky L, Hahnfeldt P, Kaplan I, Hsiao P, Chang C, Loda M. 1997. Heterogeneity of androgen receptor content in advanced prostate cancer. Mod Pathol 10:839-845.
81. Mahajan NP, Liu Y, Majumder S, Warren MR, Parker CE, Mohler JL, Earp HS, Whang YE. 2007. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc Natl Acad Sci USA 104:8438-8443.
82. Manni A, Santen RJ, Boucher AE, Lipton A, Harvey H, Simmonds M, White-Hershey D, Gordon RA, Rohner T, Drago J, et al. 1986. Hormone stimulation and chemotherapy in advanced prostate cancer: interim analysis of an ongoing randomized trial. Anticancer Res 6:309-314.
83. Marcelli M, Ittmann M, Mariani S, Sutherland R, Nigam R, Murthy L, Zhao Y, DiConcini D, Puxeddu E, Esen A, Eastham J, Weigel NL, Lamb DJ. 2000. Androgen receptor mutations in prostate cancer. Cancer Res 60:944-949.
84. Matias PM, Carrondo MA, Coelho R, Thomaz M, Zhao XY, Wegg A, Crusius K, Egner U, Donner P. 2002. Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer. J Med Chem 45:1439-1446.
85. McDonald S, Brive L, Agus DB, Scher HI, Ely KR. 2000. Ligand responsiveness in human prostate cancer: structural analysis of mutant androgen receptors from LNCaP and CWR22 tumors. Cancer Res 60:2317-2322.
86. McEwan IJ. 2004. Molecular mechanisms of androgen receptor-mediated gene regulation: structure-function analysis of the AF-1 domain. Endocr Relat Cancer 11:281-293.
87. McEwan IJ, Lavery D, Fischer K, Watt K. 2007. Natural disordered sequences in the amino terminal domain of nuclear receptors: lessons from the androgen and glucocorticoid receptors. Nucl Recept Signal 5:e001.
88. Mimeault M, Batra SK. 2006. Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis 27:1-22.
89. Mizokami A, Koh E, Fujita H, Maeda Y, Egawa M, Koshida K, Honma S, Keller ET, Namiki M. 2004. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res 64:765-771.
90. Monge A, Jagla M, Lapouge G, Sasorith S, Cruchant M, Wurtz JM, Jacqmin D, Bergerat JP, Ceraline J. 2006. Unfaithfulness and promiscuity of a mutant androgen receptor in a hormone-refractory prostate cancer. Cell Mol Life Sci 63:487-497.
91. Mononen N, Syrjakoski K, Matikainen M, Tammela TL, Schleutker J, Kallioniemi OP, Trapman J, Koivisto PA. 2000. Two percent of Finnish prostate cancer patients have a germ-line mutation in the hormone-binding domain of the androgen receptor gene. Cancer Res 60:6479-6481.
92. Nazareth LV, Stenoien DL, Bingman WE, 3rd, James AJ, Wu C, Zhang Y, Edwards DP, Mancini M, Marcelli M, Lamb DJ, Weigel NL. 1999. A C619Y mutation in the human androgen receptor causes inactivation and mislocalization of the receptor with concomitant sequestration of SRC-1 (steroid receptor coactivator 1). Mol Endocrinol 13:2065-2075.
93. Newmark JR, Hardy DO, Tonb DC, Carter BS, Epstein JI, Isaacs WB, Brown TR, Barrack ER. 1992. Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci USA 89:6319-6323.
94. Ozers MS, Marks BD, Gowda K, Kupcho KR, Ervin KM, De Rosier T, Qadir N, Eliason HC, Riddle SM, Shekhani MS. 2007. The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay. Biochemistry 46:683-695.
95. Palazzolo I, Gliozzi A, Rusmini P, Sau D, Crippa V, Simonini F, Onesto E, Bolzoni E, Poletti A. 2008. The role of the polyglutamine tract in androgen receptor. J Steroid Biochem Mol Biol 108:245-253.
96. Papaioannou M, Reeb C, Asim M, Dotzlaw H, Baniahmad A. 2005. Co-activator and co-repressor interplay on the human androgen receptor. Andrologia 37:211-212.
97. Quayle SN, Mawji NR, Wang J, Sadar MD. 2007. Androgen receptor decoy molecules block the growth of prostate cancer. Proc Natl Acad Sci USA 104:1331-1336.
98. Reddy GP, Barrack ER, Dou QP, Menon M, Pelley R, Sarkar FH, Sheng S. 2006. Regulatory processes affecting androgen receptor expression, stability, and function: potential targets to treat hormone-refractory prostate cancer. J Cell Biochem 98:1408-1423.
99. Robzyk K, Oen H, Buchanan G, Butler LM, Tilley WD, Mandal AK, Rosen N, Caplan AJ. 2007. Uncoupling of hormone-dependence from chaperone-dependence in the L701H mutation of the androgen receptor. Mol Cell Endocrinol 268:67-74.
100. Rodan GA. 2003. The development and function of the skeleton and bone metastases. Cancer 97(Suppl):726-732.
101. Rosenfeld MG, Glass CK. 2001. Coregulator codes of transcriptional regulation by nuclear receptors. J Biol Chem 276:36865-36868.
102. Ruizeveld de Winter JA, Janssen PJ, Sleddens HM, Verleun-Mooijman MC, Trapman J, Brinkmann AO, Santerse AB, Schroder FH, van der Kwast TH. 1994. Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol 144:735-746.
103. Rundlett SE, Wu XP, Miesfeld RL. 1990. Functional characterizations of the androgen receptor confirm that the molecular basis of androgen action is transcriptional regulation. Mol Endocrinol 4:708-714.
104. Salas TR, Kim J, Vakar-Lopez F, Sabichi AL, Troncoso P, Jenster G, Kikuchi A, Chen SY, Shemshedini L, Suraokar M, Logothetis CJ, DiGiovanni J, Lippman SM, Menter DG. 2004. Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity. J Biol Chem 279:19191-19200.
105. Sanchez D, Rosell D, Honorato B, Lopez J, Arocena J, Sanz G. 2006. Androgen receptor mutations are associated with Gleason score in localized prostate cancer. BJU Int 98:1320-1325.
106. Sato M, Johnson M, Zhang L, Gambhir SS, Carey M, Wu L. 2005. Functionality of androgen receptor-based gene expression imaging in hormone refractory prostate cancer. Clin Cancer Res 11:3743-3749.
107. Scher HI, Kelly WK. 1993. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 11:1566-1572.
108. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, Harwood J, Bismar TA, Kim R, Rubin MA, Pienta KJ. 2004. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 64:9209-9216.
109. Shang Y, Myers M, Brown M. 2002. Formation of the androgen receptor transcription complex. Mol Cell 9:601-610.
110. Shen HC, Coetzee GA. 2005. The androgen receptor: unlocking the secrets of its unique transactivation domain. Vitam Horm 71:301-319.
111. Shi XB, Ma AH, Xia L, Kung HJ, de Vere White RW. 2002. Functional analysis of 44 mutant androgen receptors from human prostate cancer. Cancer Res 62:1496-1502.
112. Simental JA, Sar M, Lane MV, French FS, Wilson EM. 1991. Transcriptional activation and nuclear targeting signals of the human androgen receptor. J Biol Chem 266:510-518.
113. Song LN, Herrell R, Byers S, Shah S, Wilson EM, Gelmann EP. 2003. Beta-catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcription. Mol Cell Biol 23:1674-1687.
114. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP. 2006. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66:2815-2825.
115. Steers WD. 2001. 5alpha-reductase activity in the prostate. Urology 58(Suppl 1):17-24; discussion 24.
116. Steiner H, Godoy-Tundidor S, Rogatsch H, Berger AP, Fuchs D, Comuzzi B, Bartsch G, Hobisch A, Culig Z. 2003. Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway. Am J Pathol 162:655-663.
117. Suzuki H, Sato N, Watabe Y, Masai M, Seino S, Shimazaki J. 1993. Androgen receptor gene mutations in human prostate cancer. J Steroid Biochem Mol Biol 46:759-765.
118. Tan J, Sharief Y, Hamil KG, Gregory CW, Zang DY, Sar M, Gumerlock PH, deVere White RW, Pretlow TG, Harris SE, Wilson EM, Mohler JL, French FS. 1997. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 11:450-459.
119. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP. 1995. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332:1393-1398.
120. Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, Balk SP. 1999. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 59:2511-2515.
121. Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW, Vogelzang NJ. Small EJ, Cancer and Leukemia Group B Study 9663. 2003. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 21:2673-2678.
122. Tepper CG, Boucher DL, Ryan PE, Ma AH, Xia L, Lee LF, Pretlow TG, Kung HJ. 2002. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res 62:6606-6614.
123. Thompson J, Hyytinen ER, Haapala K, Rantala I, Helin HJ, Janne OA, Palvimo JJ, Koivisto PA. 2003. Androgen receptor mutations in high-grade prostate cancer before hormonal therapy. Lab Invest 83:1709-1713.
124. Tilley WD, Buchanan G, Hickey TE, Bentel JM. 1996. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 2:277-285.
125. Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, Marcelli M. 2004. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res 64:7156-7168.
126. Vashchenko N, Abrahamsson PA. 2005. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol 47:147-155.
127. Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, van Rooij HC, Trapman J, Brinkmann AO, Mulder E. 1990. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173:534-540.
128. Verras M, Brown J, Li X, Nusse R, Sun Z. 2004. Wnt3a growth factor induces androgen receptor-mediated transcription and enhances cell growth in human prostate cancer cells. Cancer Res 64:8860-8866.
129. Verras M, Sun Z. 2006. Roles and regulation of Wnt signaling and beta-catenin in prostate cancer. Cancer Lett 237:22-32.
130. Verrijdt G, Haelens A, Claessens F. 2003. Selective DNA recognition by the androgen receptor as a mechanism for hormone-specific regulation of gene expression. Mol Genet Metab 78:175-185.
131. Verrijdt G, Tanner T, Moehren U, Callewaert L, Haelens A, Claessens F. 2006. The androgen receptor DNA-binding domain determines androgen selectivity of transcriptional response. Biochem Soc Trans 34:1089-1094.
132. Wang L, Hsu CL, Chang C. 2005. Androgen receptor corepressors: an overview. Prostate 63:117-130.
133. Wang Q, Li W, Liu XS, Carroll JS, Janne OA, Keeton EK, Chinnaiyan AM, Pienta KJ, Brown M. 2007. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell 27:380-392.
134. Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan DH, Hung MC. 2000. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 60:6841-6845.
135. Wilson CM, Griffin JE, Wilson JD, Marcelli M, Zoppi S, McPhaul MJ. 1992. Immunoreactive androgen receptor expression in subjects with androgen resistance. J Clin Endocrinol Metab 75:1474-1478.
136. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C. 1999. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA 96:5458-5463.
137. Yuan TC, Veeramani S, Lin FF, Kondrikou D, Zelivianski S, Igawa T, Karan D, Batra SK, Lin MF. 2006. Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells. Endocr Relat Cancer 13:151-167.
138. Zhao XY, Boyle B, Krishnan AV, Navone NM, Peehl DM, Feldman D. 1999. Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a. J Urol 162:2192-2199.
139. Zhou ZX, Sar M, Simental JA, Lane MV, Wilson EM. 1994. A ligand-dependent bipartite nuclear targeting signal in the human androgen receptor. Requirement for the DNA-binding domain and modulation by NH2-terminal and carboxylterminal sequences. J Biol Chem 269:13115-13123.
140. Zhu H, Mazor M, Kawano Y, Walker MM, Leung HY, Armstrong K, Waxman J, Kypta RM. 2004. Analysis of Wnt gene expression in prostate cancer: mutual inhibition by WNT11 and the androgen receptor. Cancer Res 64:7918-7926.